Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | WEE1 | P30291 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20180575 | 0.84 | NR1H2 (0.44) | NOTUMWEE1BAZ2BNAMPTHSD17B3 | |
| SCHEMBL11988475 | 0.84 | NOTUM (0.42) | NOTUMDPP8DPP9DPP7BAZ2B | |
| SCHEMBL20883595 | 0.82 | HSP90AA1 (0.41) | NOTUMWEE1RAB9ANPC1 | |
| SCHEMBL20883922 | 0.82 | NOTUM (0.38) | NOTUMWEE1RAB9ANPC1 | |
| SCHEMBL22765655 | 0.80 | NOTUM (0.58) | NOTUM | |
| SCHEMBL20704237 | 0.80 | DPP7 (0.45) | DPP7BAZ2BRAB9ANPC1NAMPT | |
| SCHEMBL20889887 | 0.78 | NOTUM (0.35) | NOTUMWEE1 | |
| SCHEMBL10150901 | 0.77 | NOTUM (0.62) | NOTUMDPP8DPP9DPP7BAZ2B | |
| SCHEMBL13573992 | 0.76 | KDM4E (0.47) | WEE1PARP1SIGMAR1 | |
| SCHEMBL7992940 | 0.75 | NOTUM (0.65) | NOTUMDPP8DPP9DPP7BAZ2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020210380-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | IMPACT THERAPEUTICS, INC (CN) | 2020-07-07 | — | — | US | disclosed |
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | Impact Therapeutics (Shanghai), Inc (CN) | 2019-10-10 | — | — | US | disclosed |
| EP-3543242-A1 | 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND | Impact Therapeutics, Inc (CN) | 2019-09-25 | — | — | EP | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308984-A1 | 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES | WEE1, WEE2, CCNE1 | NOTUM 366/4885DPP8 321/4885DPP9 1144/4885 |
| US-10703759-B2 | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones | WEE1, WEE2, CCNE1 | NOTUM 366/4885DPP8 321/4885DPP9 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.